-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $9

Benzinga·11/05/2026 21:26:34
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $10 to $9.